Methods of treating steroid-induced obesity using GLP-1 agonists

• US 8,853,157 B2
• Filed: 02/26/2013
• Issued: 10/07/2014
• Est. Priority Date: 06/11/2004
• Status: Expired due to Fees

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: Knudsen, Sanne Moeller, Rimvall, Karin
• Primary Examiner(s): Chandra, Gyan
• Application Number:
  US13/776,839
• Publication Number:
  US 20130165370A1
• Time in Patent Office: 588 Days
• Field of Search: None
• US Class Current: 514/7.2
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/26 Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics

Abstract

The present invention describes administering a GLP-1 agonist to treat obesity caused by the administration of an obesity-inducing drug.

Claims

1. A method of treating steroid-induced obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a GLP-1 agonist for reducing body weight in said subject administered a steroid, wherein the GLP-1 agonist is Arg³⁴Lys²⁶(N^ε

-(γ

-Glu(N^ε

-hexadecanoyl)))-GLP-1(7-37).

2. The method of claim 1, wherein the subject has a body mass index (BMI) of at least 30.

3. The method of claim 1, wherein the subject has a BMI of at least 27.

4. The method of claim 1, wherein the subject has a BMI of at least 25.

5. The method of claim 1, wherein the subject'"'"'s weight is about 7% over ideal.

6. The method of claim 1, wherein the subject, within the past year of steroid treatment, has gained about 1, 2, 3, 4, 5, 6, or 7% body weight.

7. The method of claim 1, wherein the subject, within the past year of steroid treatment, has gained about 7% body weight.

8. The method of claim 1, wherein the subject, within the past six months of steroid treatment, has gained about 7% body weight.

9. The method of claim 1, wherein the GLP-1 agonist is administered concurrently with the daily dosage of the steroid.

10. The method of claim 1, wherein the GLP-1 agonist is administered prior to the daily dosage of the steroid.

11. The method of claim 1, wherein the GLP-1 agonist is administered after the daily dosage of the steroid.

12. The method of claim 1, wherein the GLP-1 agonist is administered to the subject prior to the onset of obesity.

13. The method of claim 1, wherein the GLP-1 agonist is administered at the start of the subject'"'"'s steroid therapy.

14. The method of claim 1, wherein the GLP-1 agonist is administered in connection with a meal.